ライフサイエンスコーパス: prosthetic valve

1 eart valve and 2620 other patients without a prosthetic valve.

2 whether the infection occurs in a native or prosthetic valve.

3 d abnormal FDG uptake around the site of the prosthetic valve.

4 morbillorum endocarditis in a patient with a prosthetic valve.

5 sthetic valve compared with the conventional prosthetic valve.

6 lve explant caused by PVR for Silzone-coated prosthetic valve.

7 the need for long-term anticoagulation or a prosthetic valve.

8 nt difference in survival related to type of prosthetic valve.

9 ion as the etiology of obstructed mechanical prosthetic valves.

10 lve replacement with tissue versus nontissue prosthetic valves.

11 ves, 33 cases occurred, and in patients with prosthetic valves, 12 cases occurred.

12 etic valve, 29 of 285 (10%) and conventional prosthetic valve, 21 of 290 (7%, p = NS); the severity o

13 PVR was present in 50 valves: Silzone-coated prosthetic valve, 29 of 285 (10%) and conventional prost

14 s 17; P=0.046) and had a better knowledge of prosthetic valves (85% versus 68%; P=0.004).

15 left ventricular assist device infection and prosthetic valve and pacemaker endocarditis.

16 Reviewers were blinded to the type of prosthetic valve and the demographic and clinical variab

17 in 23 patients presenting with 24 obstructed prosthetic valves and compared the findings to pathology

18 e diagnosis of endocarditis in patients with prosthetic valves and in those in whom TTE indicated an

19 hould be reserved only for patients who have prosthetic valves and in whom TTE is either technically

20 diagnosis of infective endocarditis (IE) in prosthetic valves and intracardiac devices is challengin

21 infections of prosthetic devices, including prosthetic valves and intravascular catheters, S. epider

22 Recent developments guiding the choice of prosthetic valves and trends in in-hospital mortality ra

23 lied to guide the design and implantation of prosthetic valves, and have potential clinical utility a

24 Previous studies indicate that a minimal prosthetic valve area index (VAI) of > or = 0.9 cm2/m2 f

25 VAI was calculated from the ratio of prosthetic valve area to body surface area for each pati

26 Adding abnormal FDG uptake around the prosthetic valve as a new major criterion significantly

27 tensity of the mass obstructing a mechanical prosthetic valve can help differentiate pannus formation

28 nce or severity of PVR in the Silzone-coated prosthetic valve compared with the conventional prosthet

29 Prosthetic valves currently used in children lack the ab

30 endations are provided for the evaluation of prosthetic valve (dys)function.

31 At 5 years, 3 patients (3.4%) had moderate prosthetic valve dysfunction (moderate transvalvular reg

32 14 years) patients with suspected mechanical prosthetic valve dysfunction assessed by transesophageal

33 uishing pannus and thrombus in patients with prosthetic valve dysfunction is essential for the select

34 unctive value in the difficult assessment of prosthetic valve dysfunction.

35 es amenable to thrombolysis in patients with prosthetic valve dysfunction.

36 follow-up shows no evidence of restenosis or prosthetic valve dysfunction.

37 company the high-shear state associated with prosthetic valve dysfunction.

38 ne-coated prosthetic valve or a conventional prosthetic valve; early clinical reports showed higher r

39 Prosthetic valve endocarditis (PVE) after TAVI is a seri

40 Prosthetic valve endocarditis (PVE) is associated with s

41 but can be inconclusive in patients in whom prosthetic valve endocarditis (PVE) is suspected.

42 tomography ((18)F-FDG PET/CT) for diagnosing prosthetic valve endocarditis (PVE).

43 es of infections of prosthetic heart valves (prosthetic valve endocarditis [PVE]) and an increasingly

44 Prosthetic valve endocarditis accounts for a high percen

45 13, over 100 cases of Mycobacterium chimaera prosthetic valve endocarditis and disseminated disease w

46 We report a case of R. mucilaginosa prosthetic valve endocarditis and review the literature

47 value, TEE is essential in the evaluation of prosthetic valve endocarditis and the paravalvular compl

48 e describe a case of bacteremia and possibly prosthetic valve endocarditis by this organism in a noni

49 Prosthetic valve endocarditis is an uncommon manifestati

50 ococcus epidermidis, 20 skin isolates and 19 prosthetic valve endocarditis isolates were characterize

51 e patients aged between 49 and 64 years with prosthetic valve endocarditis or vascular graft infectio

52 s for PET were oncology (n=26), suspicion of prosthetic valve endocarditis subsequently excluded (n=1

53 hom 81% had congenital heart disease, 8% had prosthetic valve endocarditis, and 5% had rheumatic hear

54 For all patients with prosthetic valve endocarditis, bioprosthetic valves are

55 cently acknowledged as a diagnostic tool for prosthetic valve endocarditis, but its specificity is li

56 Propionibacterium acnes bacteremia and late prosthetic valve endocarditis, complicated by an aortic

57 no reports of operative (30-day) mortality, prosthetic valve endocarditis, renal failure necessitati

58 th; demographic and clinical findings (i.e., prosthetic valve endocarditis, thromboembolism, bleeding

59 l nervous system shunt infections, native or prosthetic valve endocarditis, urinary tract infections,

60 ed when interpreting FDG PET/CT in suspected prosthetic valve endocarditis, with specific attention t

61 in some cases of apparently culture-negative prosthetic valve endocarditis.

62 describe a case of Mycobacterium mageritense prosthetic valve endocarditis.

63 and pulmonary atresia, and 4 of 54 (8%) with prosthetic valve endocarditis.

64 degeneration, nonstructural dysfunction, or prosthetic valve endocarditis.

65 Excluding those patients who had initial prosthetic valve explant, the two-year echocardiographic

66 Signs of moderate prosthetic valve failure were observed in 3.4% of patien

67 To review the current literature on prosthetic valve function and para-valvular regurgitatio

68 1 month, and 2 months demonstrated excellent prosthetic valve function with a low transvalvular gradi

69 on the outcome of Staphylococcus aureus (SA) prosthetic valve infective endocarditis (PVIE) is unreso

70 lling 4166 patients with definite native- or prosthetic-valve infective endocarditis from 61 centers

71 re routine surveillance within 3 years after prosthetic valve insertion (73 [17.1%]), routine surveil

72 The effective orifice area (EOA) of a prosthetic valve is superior to transvalvular gradients

73 eciding between bioprosthetic and mechanical prosthetic valves is challenging because long-term survi

74 nction of thrombus from pannus on obstructed prosthetic valves is essential because thrombolytic ther

75 Abnormal prosthetic valve motion was detected by TEE in all cases

76 o underwent echocardiography (Silzone-coated prosthetic valve, n = 285 and conventional prosthetic va

77 d prosthetic valve, n = 285 and conventional prosthetic valve, n = 290), 59% had prosthetic aortic va

78 and when valve involvement (especially of a prosthetic valve) needs to be excluded during febrile ep

79 elevated mean LA pressures in the absence of prosthetic valve obstruction or regurgitation.

80 tion of patients for thrombolytic therapy of prosthetic valve obstruction.

81 andomized to receive either a Silzone-coated prosthetic valve or a conventional prosthetic valve; ear

82 ents admitted to our hospital with suspected prosthetic valve or cardiac device IE between November 2

83 (1.8%) had endocarditis (20 native valve, 29 prosthetic valve or device) due to non-HACEK, gram-negat

84 odified DC in patients with suspected IE and prosthetic valves or cardiac devices.

85 alve (P<0.001) and 78% of patients without a prosthetic valve (P<0.001).

86 (P<0.001), and in 4.9% of patients without a prosthetic valve (P<0.001).

87 (P=1.000), and in 0.2% of patients without a prosthetic valve (P=0.025).

88 coated prosthetic valve vs. 94% conventional prosthetic valve, p = NS).

89 Association functional class I/II with good prosthetic valve performance.

90 e kidney injury, vascular complications, and prosthetic valve performance.

91 inconclusive, particularly in patients with prosthetic valves (PVs) and implantable cardiac electron

92 ay be a reasonable alternative to mechanical prosthetic valve replacement in patients aged 50 to 69 y

93 iabetes, renal failure, aortic stenosis, and prosthetic valve replacement.

94 icular function, urgent or emergency status, prosthetic valve size < or = 23 mm and hospital activity

95 5% CI 1.14 to 11.89), and increased ratio of prosthetic valve size to patient weight (relative risk 1

96 Reasons for second MVR were prosthetic valve stenosis 24 (83%), thrombosis 4 (14%),

97 Compared with nontissue prosthetic valves, the use of tissue valves was not pred

98 stratify patients undergoing thrombolysis of prosthetic valve thrombosis (PVT).

99 Prosthetic valve thrombosis during pregnancy is life-thr

100 consecutive women in 25 pregnancies with 28 prosthetic valve thrombosis episodes (obstructive, n=15;

101 rombolytic success rate for the treatment of prosthetic valve thrombosis in pregnant women.

102 e plasminogen activator for the treatment of prosthetic valve thrombosis in pregnant women.

103 first-line therapy in pregnant patients with prosthetic valve thrombosis.

104 s therefore recommended in the management of prosthetic valve thrombosis.

105 ereafter, the authors: 1) review the data on prosthetic valve thrombosis; 2) discuss the pathophysiol

106 of acute insertion of a second transcatheter prosthetic valve (TV) within the first (TV-in-TV) or tra

107 gestive heart failure, native valve disease, prosthetic valve type, preoperative catheterization data

108 equency of valve repair, higher frequency of prosthetic valve usage in elderly patients, and lower ad

109 24-month event-free rate: 93% Silzone-coated prosthetic valve vs. 94% conventional prosthetic valve,

110 he videointensity of the mass to that of the prosthetic valve, was lower in the thrombus group (0.46+

111 Mechanical prosthetic valves were associated with lower risk of reo

112 late might be reconsidered for patients with prosthetic valves, who require life-long anticoagulation

113 technology that allows for implantation of a prosthetic valve without open heart surgery.